Medprin Regenerative Medical Technologies Co. Ltd.

Medprin Regenerative Medical Technologies Co. Ltd.

SSZSE:301033
49.17
CNY
-0.38
(-0.77%)
1.90EPS
28.14P/E
3.63BMarket Cap
Apr 16Next Earn

Total Valuation

CNY

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. carries a market capitalization of 3.63B, placing it among publicly traded companies globally. Its enterprise value stands at 3.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.63B
Enterprise Value3.31B

Important Dates

Medprin Regenerative Medical Technologies Co. Ltd.'s next confirmed earnings release is scheduled for April 16, 2027.

Earnings Date4/16/2027

Share Statistics

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. has 67.63M shares outstanding.

Shares Outstanding67.63M

Valuation Ratios

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. trades at a trailing price-to-earnings ratio of 28.14. The price-to-sales ratio is 8.68, and the price-to-book ratio stands at 4.20.

PE Ratio28.14
PS Ratio8.68
PB Ratio4.20
P/TBV Ratio4.75

Enterprise Valuation

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. trades at an EV/EBITDA multiple of 23.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.31B versus a market cap of 3.63B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.01
EV / EBITDA23.19
EV / EBIT23.19

Financial Position

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. maintains a current ratio of 9.60, meaning it holds 9.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.09, indicating moderate leverage, while an interest coverage ratio of 1,701.54 demonstrates limited ability to service its debt obligations.

Current Ratio9.60
Quick Ratio7.61
Debt / Equity1.09
Debt / EBITDA0.07
Interest Coverage1,701.54

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. posted a return on equity (ROE) of 16.16, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.00 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.49, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.07, useful for judging operating efficiency across full business cycles. The company generates approximately 919,831.15 in revenue per employee across its workforce of 450.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.94 indicates how many times Medprin Regenerative Medical Technologies Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)16.16
Return on Assets (ROA)14.49
Return on Invested Capital (ROIC)16.00
Return on Capital Employed (ROCE)16.07
Revenue Per Employee919,831.15
Employee Count450.00
Inventory Turnover1.94

Taxes

CNY

Over the twelve months ended September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. recorded 13.91M in income tax expense. That works out to an effective tax rate of 9.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 141.58M, leaving 127.67M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax13.91M
Effective Tax Rate9.82

Stock Price Statistics

CNY

As of the close on November 17, 2026, Medprin Regenerative Medical Technologies Co. Ltd.'s stock has declined approximately 26.69% over the past 52 weeks. The 50-day moving average sits at 52.26, while the 200-day moving average is 57.62.

52-Week Price Change-26.69%
50-Day Moving Average52.26
200-Day Moving Average57.62

Income Statement

CNY

Over the twelve months ended September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. generated 413.92M in revenue and converted that into 127.67M in net income, yielding earnings per share of 1.90. EBITDA reached 142.94M, while operating income came in at 146.30M.

Revenue413.92M
Gross Profit330.77M
Operating Income146.30M
Pretax Income141.58M
Net Income127.67M
EBITDA142.94M
EBIT142.94M
Earnings Per Share (EPS)1.90

Balance Sheet

CNY

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. holds 323.80M in cash and equivalents against 9.45M in total debt, resulting in a net debt position of -124.31M. Total book value stands at 863.92M, with working capital of 365.67M providing operational flexibility.

Cash & Cash Equivalents323.80M
Total Debt9.45M
Net Debt-124.31M
Equity (Book Value)863.92M
Book Value Per Share12.77
Working Capital365.67M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-39.69M

Margins

Over the twelve months ended September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. posted a gross margin of 79.91, reflecting its pricing power and cost economics. The operating margin of 35.34 and net profit margin of 30.84 provide insight into operational efficiency.

Gross Margin79.91
Operating Margin35.34
Pretax Margin34.20
Profit Margin30.84
EBITDA Margin34.53

Scores

As of September 30, 2026, Medprin Regenerative Medical Technologies Co. Ltd. has an Altman Z-Score of 25.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score25.45